...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>CNS drugs >Glatiramer acetate: A review of its use in patients with relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis
【24h】

Glatiramer acetate: A review of its use in patients with relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis

机译：醋酸格拉替雷：其在复发缓解型多发性硬化症患者中的应用及其在延迟临床明确的多发性硬化症发作中的应用

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Glatiramer acetate (Copaxone?) is a synthetic analogue of the multiple sclerosis (MS)-associated antigen, myelin basic protein. Although its exact mechanisms of action in MS remain to be fully elucidated, the key mechanisms of action of glatiramer acetate appear to be modulation of the inflammatory response and neuroprotective and/or neuroregenerative effects. Subcutaneous glatiramer acetate is indicated for the treatment of adult patients with relapsing-remitting MS (RRMS) and the treatment of patients who have experienced a well-defined first clinical episode and have magnetic resonance imaging (MRI) features consistent with MS or have been determined to be at high risk of developing clinically definite MS (CDMS). In clinical trials in patients with RRMS, glatiramer acetate reduced the frequency of relapses and reduced the burden and activity of disease on MRI, was more effective than placebo and showed generally similar efficacy to subcutaneous interferon (IFN) β-1a and IFNβ-1b. Furthermore, the beneficial effects of glatiramer acetate were sustained during up to 15 years of treatment in an extension study. In patients with clinically isolated syndrome (CIS), glatiramer acetate significantly delayed the onset of CDMS compared with placebo. The drug was generally well tolerated in these patient populations, with injection-site reactions being the most commonly occurring adverse events. Therefore, glatiramer acetate remains a valuable first-line option in the treatment of RRMS and is an option for delaying the onset of CDMS in patients with CIS.
机译：醋酸格拉替雷（Copaxone？）是多发性硬化症（MS）相关抗原髓磷脂碱性蛋白的合成类似物。尽管其在MS中的确切作用机制仍有待充分阐明，但醋酸格拉替雷的主要作用机制似乎是调节炎症反应以及神经保护和/或神经再生作用。醋酸格拉替雷皮下注射剂可用于治疗复发缓解型MS（RRMS）的成年患者，以及已经历明确的首次临床发作并具有与MS一致的磁共振成像（MRI）特征或已被确定的患者有发展临床定性MS（CDMS）的高风险。在RRMS患者的临床试验中，醋酸格拉替雷降低了复发频率，降低了MRI疾病的负担和活性，比安慰剂更有效，并且显示出与皮下干扰素（IFN）β-1a和IFNβ-1b大致相似的功效。此外，在扩展研究中，醋酸格拉替雷的有益作用在长达15年的治疗中得以持续。与安慰剂相比，在临床孤立综合征（CIS）患者中，醋酸格拉替雷显着延迟了CDMS的发作。在这些患者人群中，该药物通常具有良好的耐受性，其中注射部位反应是最常见的不良事件。因此，醋酸格拉替雷仍然是治疗RRMS的有价值的一线选择，并且是延迟CIS患者CDMS发作的选择。

著录项

  • 来源
    《CNS drugs》 |2013年第11期|共18页
  • 作者

    ScottL.J.;

  • 作者单位
  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号